Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | LYN | P07948 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9436834 | 0.67 | MAPK13 (0.33) | AURKACDK1LYNPIM1FGFR1 | |
| SCHEMBL1437770 | 0.62 | — | — | |
| SCHEMBL4190693 | 0.60 | CHEK1 (0.32) | — | |
| SCHEMBL336074 | 0.60 | — | — | |
| SCHEMBL1064468 | 0.58 | SLC2A1 (0.36) | — | |
| SCHEMBL5816913 | 0.57 | AURKA (0.30) | AURKACDK1LYNPIM1FGFR1 | |
| SCHEMBL7831389 | 0.57 | — | — | |
| SCHEMBL18304700 | 0.54 | CES1 (0.37) | — | |
| SCHEMBL9297171 | 0.54 | GSK3B (0.39) | AURKACDK1LYNPIM1FGFR1 | |
| SCHEMBL11831515 | 0.54 | IDO1 (0.43) | AURKACDK1LYNPIM1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006086545-A2 | METHOD TO IDENTIFY NOVEL THERAPEUTICS | DESIMONE ROBERT W (US) | 2006-08-17 | — | — | WO | claimed |
| EP-3240791-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| EP-2035006-A1 | USE OF ALLOPURINOL FOR THE TREATMENT OF PALMAR PLANTAR ERYTHRODYSESTHESIA | Nobera Pharma, S.L. (ES) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007138103-A1 | USE OF ALLOPURINOL FOR THE TREATMENT OF PALMAR PLANTAR ERYTHRODYSESTHESIA | NOBERA PHARMA, S.L. (ES) | 2007-12-06 | — | — | WO | disclosed |
| EP-1807429-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM, LLC (BM) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007041388-A2 | PREVENTION AND TREATMENT OF HEARING DISORDERS | CYPRESS BIOSCIENCE, INC (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007012064-A2 | PREVENTION AND TREATMENT OF HEARING DISORDERS | CYPRESS BIOSCIENCE, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | disclosed |
| EP-1572097-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005065668-A2 | TOPICAL COMPOSITIONS COMPRISING HALO-DEOXYADENOSINES FOR TREATMENT OF SKIN DISORDERS | QLT USA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004028481-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-1997025988-A1 | METHODS OF TREATING OR PREVENTING PAIN OR NOCICEPTION | ELI LILLY AND COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |